Review Article

ADRB2 Arg16Gly Polymorphism and Pulmonary Function Response of Inhaled Corticosteroids plus Long-Acting Beta Agonists for Asthma Treatment: A Systematic Review and Meta-Analysis

Xi Wang, Qian Li, Ruming Liu, Jin He, Di Wu, Yun Wang, and Jun Zhang

The Department of Clinical Pharmacy, The First Affiliated Hospital of Kunming Medical University, Kunming, China

Correspondence should be addressed to Jun Zhang; zhangjun_pharmacy@163.com

Received 22 June 2017; Revised 21 September 2017; Accepted 12 October 2017; Published 21 January 2018

Academic Editor: Jörg D. Leuppi

Copyright © 2018 Xi Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The beta-2 adrenergic receptor (ADRB2) Arg16Gly polymorphism may alter the bronchodilation response to long-acting beta2-agonists, thereby influencing the clinical effectiveness of LABAs plus corticosteroids (ICS) treatment. But the results of individual studies are inconclusive.

Methods. A systematic search was conducted in PubMed, Embase, the Cochrane Database, WHO International Clinical Trials Registry Platform, Chinese National Knowledge Infrastructure, Wanfang, Chinese BioMedical Literature Database, and VIP databases. The meta-analysis was performed with RevMan statistical software (version 5.2), and potential publication bias was estimated by Egger’s test using STATA (version 12.0), with $p < 0.05$ indicating significant publication bias.

Results. We found 5 cohort studies with a total of 632 patients and included them in the meta-analysis. There are no significant differences in pulmonary function response between patients with the Arg/Arg and Arg/Gly phenotype (SMD $-0.04$, 95% CI $-0.45$ to $0.37$; $p = 0.84$). There were also no significant differences in the pulmonary function response between patients with the Arg/Arg and Gly/Gly phenotype (MD $-0.03$, 95% CI $-0.07$ to $0.02$; $p = 0.28$). Conclusions. Our systematic review and meta-analysis suggest that ADRB2 Arg16Gly polymorphism is not associated with pulmonary response to asthma treatment with ICS plus LABAs.

1. Introduction

According to the World Health Organization (WHO), asthma is an important noncommunicable disease with 235 million patients worldwide in 2013. The combination of inhaled corticosteroids (ICS) and long-acting beta2-agonists (LABAs) is a widely used maintenance therapy for asthma. Recent studies have revealed that beta-2 adrenergic receptor (ADRB2) polymorphism may mediate the bronchodilation response to LABA, thereby influencing the clinical effectiveness of combination treatment [1]. However, reports of the effect of Arg16Gly polymorphism on ADRB2 function are not conclusive [2, 3]. Some found no significant differences in the improvement of pulmonary function in asthmatic patients with different ADRB2 genotypes [4, 5]. Others found that the effectiveness of ICS and LABAs treatment was increased in asthma patients with the Arg/Arg phenotype [6]. We performed a systematic review and meta-analysis to investigate the association of Arg16Gly polymorphism of ADRB2 and pulmonary function response of LABAs plus ICS combination treatment in asthma patients.

2. Methods

We followed the STREGA (Strengthening the REporting of Genetic Association) guidelines to review the methods and results of studies reporting on the influence of ADRB2 Arg16Gly polymorphism on the pulmonary function response of ICS and LABAs treatment of asthma patients.

2.1. Literature Search. Two investigators (Wang and Li) independently searched PubMed, Embase, the Cochrane Database, WHO International Clinical Trials Registry
A quality assessment of the studies was performed independently by two observers using the Newcastle-Ottawa Scale (NOS) criteria, which include scoring of the method of group selection, comparability of participants, and clinical outcomes. The highest score is 9, and a score ≥ 6 indicates high methodological quality. Differences were resolved by discussion.

2.4. Statistical Analysis. The meta-analysis was performed with RevMan statistical software (version 5.2), and potential publication bias was estimated by Egger’s test using STATA (version 12.0), with \( p < 0.05 \) indicating significant publication bias. The mean difference (MD) was calculated if the studies being compared used the same pulmonary function measurements, otherwise the standardized mean difference (SMD) was calculated, both with 95% confidence intervals (CIs). Study heterogeneity was assessed by the Cochran’s Q and \( I^2 \) tests.

3. Results

3.1. Studies Selection and Characteristics. 267 articles were identified by electronic and manual searches from the databases mentioned, and 246 articles were excluded based on the titles and abstracts, then 16 articles were excluded after reviewing the full text. Finally, 5 cohort studies were included in the meta-analysis, ranging from 2006 to 2015 [4, 5, 7–9]. A total of 632 patients were included: 176 patients were with ArgArg phenotype, 265 patients were with ArgGly phenotype, and 184 patients were with GlyGly phenotype.

Two studies were carried out among Chinese Han people [7, 9], one study was carried out among Iranian [8], and other studies were carried out among mixed population or population without specification [4, 5].

In three studies, the subjects were entered two or sixteen weeks run-in period, only using albuterol or ipratropium bromide as needed to relieve asthma symptoms, then entered to the treatment of FSC period [4, 5, 7]. In two studies, the subjects were directly entered to the treatment of FSC period [8, 9].

One study examined the changes of morning PEF and FEV1 from baseline at the end of 12 weeks of treatment with FSC, 250/50 µg diskus twice daily.

One study examined the changes of FEV1% predicted and FEV1/FVC from baseline at the end of 4 weeks of treatment with FSC, 250/50 µg diskus twice daily. One study examined the changes of morning PEF, afternoon PEF, and predose FEV1 from baseline at the end of 16 weeks of treatment with FSC, 100/50 µg diskus twice daily. One study examined the changes of morning PEF and FEV1 from baseline at the end of 12 weeks of treatment with FSC, 100/50 µg diskus twice daily. One study examined the changes of PEF, FEV1, and FVC from baseline at the end of 16 weeks of treatment with FSC, 100/25 µg diskus twice daily and albuterol as needed. There were no significant differences in baseline pulmonary function characteristics across the Arg16Gly genotypes in these 5 studies.
Table 1: Characteristics and methodological quality of included studies.

| First author     | Year | Ethnicity      | Case number | Age (year) | Gender (male/female) | Main drugs and dose (μg, bid) | Follow-up (week) | Outcome measure | Genotyping measurement | HWE | NOS score |
|------------------|------|----------------|-------------|------------|----------------------|-------------------------------|------------------|-------------------|----------------------|-----|-----------|
| 1 Qiu et al. [7] | 2014 | Han            | 68          | >18        | no data              | FSC (250/50)                  | 12               | AM PEF and FEV1  | Sequencing         |     |           |
| 2 Soleimani et al. [8] | 2013 | Iranian        | 28          | 27–65      | 8/18                 | FSC (250/50)                  | 4                | FEV1% predicted and FEV1/FVC | PCR-RFLP | Yes | 6        |
| 3 Bleecker et al. [5] | 2009 | Mixed population | 270        | >12        | 106/194              | FSC (100/50)                  | 16               | AM PEF, PM PEF, and FEV1 | Tag man   | —      | 7        |
| 4 Bleecker et al. [4] | 2006 | Mixed population | 183        | >15        | 81/102               | FSC (100/50)                  | 12               | AM PEF, FEV1    | Not mentioned       | Yes |           |
| 5 Wu et al. [9]  | 2015 | Han            | 83          | >5         | 48/35                | FSC (100/25)                  | 16               | FVC, FEV1, PEF  | PCR-RFLP             | Yes |           |

Figure 2: Forest plots of the association between the ADRB2 Arg16Gly polymorphism and pulmonary function response of inhaled ICS plus LABAs for asthma treatment (Arg/Arg or Arg/Gly) with 4 studies included.

Four studies include the patients with ArgArg, ArgGly, or GlyGly phenotypes, and one study include the patients with ArgArg or ArgGly phenotypes.

Direct sequencing was conducted in one study [7], PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) was conducted in the other two studies [8, 9], and TaqMan SNP Genotyping was conducted in one study [5]. No specific genotyping method was mentioned in one study [4]. The distribution of the Arg16Gly phenotypes in all included studies was in Hardy–Weinberg equilibrium (HWE), except one study chose ninety subjects per Arg16Gly phenotype [5].

The characteristics and methodological quality of studies are summarized in Table 1, with the first author’s name, year of publication, characteristics of patients, asthma treatment, genotyping measurements, and outcome measurements. All the studies were validated by NOS quality assessment.

3.2. ADRB2 Arg16Gly Polymorphism and Pulmonary Function Response of Inhaled ICS plus LABAs for Asthma Treatment. The differences of pulmonary function in patients with the Arg/Arg or Arg/Gly phenotype were investigated in 5 cohort studies with a total 417 participants. The changes of FEV1(L) were the outcome measure in 4 studies [4, 5, 7, 9]. The changes of FEV1/FEC were the outcome measure in one study [8]. First, we included the 4 studies which chose FEV1 as the outcome measure to the meta-analysis with a total 389 participants, MD of FEV1 with random-effect model was performed. As shown in Figure 2, no difference of pulmonary function was found between the two phenotypes (MD −0.01, 95% CI −0.05 to 0.03; p = 0.63). Then, we included the 5 studies to the meta-analysis with a total 417 participants, SMD with random-effect model was performed since different pulmonary functions were measured. As shown in Figure 3, no difference of pulmonary function was found between the two phenotypes either (SMD −0.04, 95% CI −0.45 to 0.37; p = 0.84). Publication bias was assessed by Egger’s test, and no significant publication bias was detected in the included studies (Table 2).

The differences of pulmonary function in patients between the two phenotypes (Arg/Arg and Gly/Gly) were investigated in 4 cohort studies with a total 352 participants. FEV1(L) was the outcome measure, and MD of FEV1 with random-effect model was performed in the analysis. As shown in Figure 4, no difference of pulmonary function was found between the two phenotypes (MD −0.03, 95% CI
Heterogeneity: $\tau^2 = 0.15$; $\chi^2 = 14.63$, df = 4 ($p = 0.006$); $I^2 = 73\%$

Test for overall effect: $Z = 0.20$ ($p = 0.84$)

Table 2: Egger’s test.

| Polymorphism         | Arg/Arg versus Arg/Gly | Arg/Arg versus Gly/Gly |
|----------------------|------------------------|------------------------|
| Numbers of studies   | 417                    | 353                    |
| $p$ value            | 0.398                  | 0.391                  |

$p < 0.05$, statistically significant publication bias.

-0.07 to 0.02; $p = 0.28$). Publication bias was assessed by Egger’s test, and no significant publication bias was detected in the included studies (Table 2)

4. Discussion

Beta2 agonist is one kind of inhaled bronchodilators, which relaxed bronchial smooth muscle by activating ADRB2 [10]. It is classified as short-acting beta agonists (SABAs) or as long-acting beta agonists (LABAs). Inhaled SABAs monotherapy is mainly used in mild or intermittent asthma patients. Since LABAs monotherapy may increase the risk of death from asthma, combination of LABAs and ICS is recommended for maintaining treatment in asthma [6]. Among around 80 identified polymorphisms in the beta-2 adrenergic receptor gene, ADRB2 Arg16Gly polymorphism is one of the most common nonsynonymous SNPs [1, 11]. ADRB2 Arg16Gly polymorphism has been shown to have functional effects in vitro. Green et al. found that human airway smooth muscle cells expressing Gly16 homozygotes resulted in enhanced ADRB2 agonist-promoted down-regulation of ADRB2 compared with Arg16 homozygotes [12]. Some studies examined the clinical effect of ADRB2 Arg16Gly polymorphism on the asthmatic patient’s response to LABAs plus ICS therapy, but the results were inconsistent [2, 6, 7]. Thus, this is the first systematic review and meta-analysis to estimate the effect of ADRB2 Arg16Gly polymorphism on pulmonary function in asthma patients treated with ICS plus LABAs. We did not find any significant differences of pulmonary function in patients with the Arg/Arg or Arg/Gly phenotype. Patients bearing the Arg/Arg or Gly/Gly phenotype also did not show significant different pulmonary functions. The meta-analysis results suggested that ADRB2 Arg16Gly polymorphism is not associated with pulmonary function response to asthma treatment with ICS plus LABAs.

Our analysis has limitations. Firstly, Egger’s test found no significant publication bias in the included studies.
However, useful data may be available in unpublished or unpresented studies and in studies that were not published in English or Chinese. Also, two potentially eligible studies were not included because of incomplete data [13, 14]. Secondly, we found significant heterogeneity among the studies, including different methods for diagnosis of asthma, different patient populations (e.g., sample size, asthma severity, age, ethnicity, and sex ratio), different fluticasone propionate and salmeterol dosage, and different treatment duration. These differences may influence the reliability of the results.

In conclusion, based on the data derived from the included studies, this systematic review and meta-analysis indicated that ArgGly polymorphism of ADRB2 may not be a predictive genetic marker of pulmonary function response to LABAs plus ICS treatment in asthma patients. Although a definitive conclusion is not possible, additional studies with larger sample sizes are warranted to address the question.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Acknowledgments
This study was supported by National Natural Science Foundation of China (Grant nos. 81360108 and 81560252), specialized fund for training of high-level talents in Health and Family Planning in Yunnan Province (Grant no. L-201614), The First Affiliated Hospital of Kunming Medical University Research Fund for the Doctor (Grant no. 2015BS002), Yunnan Applied Basic Research Projects-Joint Special Fund Project (Grant no. 2015FB029), and Health Science and Technology Internal Research Institution Project of Yunnan Province (Grant no. 2014NS190).

References
[1] J. J. Lima, “Do genetic polymorphisms alter patient response to inhaled bronchodilators?,” Expert Opinion on Drug Metabolism and Toxicology, vol. 10, no. 9, pp. 1231–1240, 2014.
[2] M. E. Wechsler, S. J. Kunselman, V. M. Chinchilli et al., “Effect of β2-adrenergic receptor polymorphism on response to long-acting β2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial,” The Lancet, vol. 374, no. 9703, pp. 1754–1764, 2009.
[3] D. K. Lee, G. P. Currie, I. P. Hall, J. J. Lima, and B. J. Lipworth, “The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol,” British Journal of Clinical Pharmacology, vol. 57, no. 1, pp. 68–75, 2004.
[4] E. R. Bleecker, S. W. Yancey, L. A. Baitinger et al., “Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma,” Journal of Allergy and Clinical Immunology, vol. 118, no. 4, pp. 809–816, 2006.
[5] E. R. Bleecker, H. S. Nelson, M. Kraft et al., “2-Receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate.” American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 7, pp. 676–687, 2009.
[6] K. Blake and J. Lima, “Pharmacogenomics of long-acting beta2-agonists,” Expert Opinion on Drug Metabolism and Toxicology, vol. 11, no. 11, pp. 1733–1751, 2015.
[7] Y. Qiu, D. Zhang, Y. Qin et al., “Effect of beta2-adrenergic receptor gene Arg16Gly polymorphisms on response to long-acting beta2-agonist in Chinese Han asthmatic patients,” Multidisciplinary Respiratory Medicine, vol. 9, no. 1, p. 22, 2014.
[8] F. Soleimani, F. Fahimi, P. Adimi Naghan et al., “The effect of polymorphisms of beta2 adrenoceptors on response to long-acting beta2 agonists in Iranian asthmatic patients,” Iranian Journal of Allergy, Asthma and Immunology, vol. 12, no. 4, pp. 383–390, 2013.
[9] Q. W. Wu, X. M. Wan, X. Zhu, X. Fu, and C. Pu, “The variation of coding region of ADRB2 gene and asthmatic children’s response to LABAs plus ICS therapy,” Pharmacotherapy (in Chinese language), vol. 20, pp. 1150–1155, 2015.
[10] R. Aalbers, C. Vogelmeier, and P. Kuna, “Achieving asthma control with ICS/LABA: a review of strategies for asthma management and prevention,” Respiratory Medicine, vol. 111, pp. 1–7, 2016.
[11] S. B. Liggett, “The pharmacogenetics of beta2-adrenergic receptors: relevance to asthma,” Journal of Allergy and Clinical Immunology, vol. 105, no. 2, pp. S487–S492, 2000.
[12] S. A. Green, J. Turki, P. Bejarano, I. P. Hall, and S. B. Liggett, “Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells,” American Journal of Respiratory Cell and Molecular Biology, vol. 13, no. 1, pp. 25–33, 1995.
[13] S. W. Yancey, M. Klotsman, H. G. Ortega, L. D. Edwards, and W. H. Anderson, “Acute and chronic lung function responses to salmeterol and salmeterol plus fluticasone propionate in relation to Arg16Gly beta(2)-adrenergic polymorphisms,” Current Medical Research and Opinion, vol. 25, no. 4, pp. 1011–1018, 2009.
[14] S. H. Kim, Y. M. Ye, G. Y. Hur et al., “Effect of beta2-adrenergic receptor polymorphism in asthma control of patients receiving combination treatment,” Yonsei Medical Journal, vol. 50, no. 2, pp. 182–188, 2009.